Skip to main content

Table 2 Summary of testing and outcomes of cases

From: The spectrum of Epstein-Barr virus infections of the central nervous system after organ transplantation

Diagnosis

Case 1: post-transplant lymphoproliferative disorder (PTLD)

Case 2: EBV encephalitis

Case 3: EBV myelitis

EBV serology

EBNA IgG −

EBV VCA IgM −

EBV VCA IgG +

EBV EA IgG +

Not performed

EBNA IgG +

EBV VCA IgM ± b

EBV VCA IgG + 

EBV EA IgG + 

EBV CSF PCR

Positive

Positive (quantitative EBV PCR: 383,000 copies/mL)

Positive

CSF profilea

WBC 12; lymphocytes 81% (occasional plasmacytoid and atypical cells)

 < 1 RBC

Protein 36

Glucose 53

WBC 171; lymphocytes 95%

RBC 234

Protein 169

Glucose 63

WBC 23; lymphocytes 95%

 < 1 RBC

Protein 60

Glucose 55

Other serum testing

CBC, CMP

California virus, East Equine encephalitis, St. Louis encephalitis, West Equine encephalitis

Treponemal antibody

ANA

HIV

QuantiFERON

Anaplasma, Ehrlichia

Lyme

Aspergillus galactomannan

Anti-aquaporin-4 IgG

Anti-MOG IgG

C-reactive protein

Vitamin B12

CBC, CMP

Treponemal antibody

HIV

QuantiFERON

Lyme

CBC, CMP

Vitamin B12

Methylmalonic acid

Copper

Vitamin E

Zinc

HIV

Lyme

Treponemal antibody

ANA

ACE

ANCA

Anti-aquaporin-4 IgG

Anti-MOG IgG

Other CSF testing

Herpes simplex virus I/II PCR

Listeria

Cryptococcal antigen

Varicella zoster PCR

Toxoplasma PCR

Tropherma whipple

Mycoplasma

Histoplasma

Cytomegalovirus PCR

Enterovirus PCR

JC virus PCR

HHV-6 PCR

Oligoclonal bands

Cytology

Flow cytometry

Herpes simplex virus I/II PCR

Cryptococcal antigen

Varicella zoster PCR

Cytomegalovirus PCR

Cytology

Flow cytometry

Universal bacterial and fungal PCR

Herpes simplex virus I/II PCR

Cryptococcal antigen

Varicella zoster PCR

Cytomegalovirus PCR paraneoplastic panel

VDRL

oligoclonal bands

West-Nile virus PCR

HHV-6 PCR

Treatment

1. rituximab, prednisone, methotrexate

2. IV ganciclovir then po valganciclovir; tacrolimus held

Mycophenolate mofetil held, tacrolimus continued; IV acyclovir then transitioned to IV ganciclovir

Mycophenolate held, tacrolimus continued; IV solumedrol

Outcome

Significant improvement 20 weeks after presentation with residual radiographic lesions

Deceased

Complete recovery 5 months later

  1. ACE, angiotensin converting enzyme; ANCA, antineutrophil cytoplasmic antibodies; ANA, antinuclear antibody; CBC, complete blood cell count; CMP, complete metabolic panel; CSF, cerebral spinal fluid; EA, early antigen; EBER, Epstein-Barr encoding region; EBNA, Epstein-Barr nuclear antigen; EBV, Epstein-Barr virus; HHV-6, Human Herpesvirus 6; HIV, human immunodeficiency virus; IV, intravenous; JC virus, John Cunningham virus; LMP1, latent membrane protein 1; MOG, myelin oligodendrocyte glycoprotein; RBC, red blood cell count; VCA, viral capsid antigen; VDRL, venereal disease research laboratory; WBC, white blood cell count
  2. aLab reference values: WBC < 10 cells/μL, RBC < 1 cells/μL, lymphocytes 40–80%, protein 15–45 mg/dL, glucose 40–70 mg/dL)
  3. b+/−Means borderline/equivocal